Iovance Biotherapeutics, Inc. (IOVA) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$3.55
Price Target
$2.00
Target Range
$2.00 — $2.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-3.3x
Forward PEG—
Implied Growth+44.6%
Median Target$2.00
Analyst Spread0.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$2
-43.7%
Consensus
$2
-43.7%
Bull Case
$2
-43.7%
IOVA Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Iovance Biotherapeutics, Inc. (IOVA) has a Wall Street consensus price target of $2.00, based on estimates from 20 covering analysts. With the stock currently trading at $3.55, this represents a potential downside of -43.7%. The company has a market capitalization of $1.27B.
Analyst price targets range from a low of $2.00 to a high of $2.00, representing a 0% spread in expectations. The median target of $2.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 15 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, IOVA trades at a trailing P/E of -3.3x. Analysts expect EPS to grow +44.6% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+189.5%
Avg Forward P/E38.2x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ADCTADC Therapeutics S.A. | $478M | $3.76 | $7.50 | +99.5% | Buy | — | 12 |
 FATEFate Therapeutics, Inc. | $280M | $2.43 | $39.50 | +1525.5% | Buy | — | 31 |
 CRSPCRISPR Therapeutics AG | $5.1B | $52.42 | $63.00 | +20.2% | Buy | — | 38 |
 NTLAIntellia Therapeutics, Inc. | $1.6B | $13.71 | $20.88 | +52.3% | Buy | — | 39 |
 BEAMBeam Therapeutics Inc. | $3.2B | $31.47 | $40.83 | +29.7% | Buy | — | 27 |
 TGTXTG Therapeutics, Inc. | $6.9B | $43.02 | $39.00 | -9.4% | Buy | 32.3x | 13 |
 KYMRKymera Therapeutics, Inc. | $6.9B | $84.63 | $117.06 | +38.3% | Buy | — | 26 |
 ALNYAlnylam Pharmaceuticals, Inc. | $39.5B | $295.91 | $445.67 | +50.6% | Buy | 44.2x | 52 |
 RCUSArcus Biosciences, Inc. | $2.5B | $24.80 | $30.00 | +21.0% | Buy | — | 18 |
 IMVTImmunovant, Inc. | $5.5B | $27.22 | $45.50 | +67.2% | Buy | — | 23 |
Upside Potential Comparison
FATEADCTIMVTNTLAALNYKYMRBEAMRCUSSee IOVA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IOVA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IOVA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIOVA — Frequently Asked Questions
Quick answers to the most common questions about buying IOVA stock.
What is the IOVA stock price target for 2026?
IOVA's consensus price target is $2, -43.7% below the current price of $3.55. The 20 analysts tracking IOVA see downside risk at present valuations.
Is IOVA a buy, sell, or hold?
IOVA has a consensus rating of "Buy" based on 20 Wall Street analysts. The rating breakdown is predominantly bullish, with 15 Buy/Strong Buy ratings. The consensus 12-month price target of $2 implies -43.7% downside from current levels.
Is IOVA stock overvalued or undervalued?
IOVA's current price is $3.55 with a consensus target of $2 (-43.7% implied move). Analyst estimates suggest the stock is overvalued at current levels.
How high can IOVA stock go?
The most bullish Wall Street analyst has a price target of $2 for IOVA, while the most conservative target is $2. The consensus of $2 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover IOVA stock?
IOVA is well covered by analysts, with 20 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 15 have Buy ratings, 5 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the IOVA stock forecast?
The 12-month IOVA stock forecast based on 20 Wall Street analysts shows a consensus price target of $2, with estimates ranging from $2 (bear case) to $2 (bull case). The median consensus rating is "Buy".
Should I buy IOVA stock?
Analysts are cautious on IOVA, with 0 Sell ratings and a price target of $2 (-43.7% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do IOVA price targets vary so much?
IOVA analyst price targets range from $2 to $2, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $2 consensus represents the middle ground.